HC Wainwright Issues Optimistic Estimate for RLAY Earnings

Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) - HC Wainwright raised their Q2 2025 earnings estimates for shares of Relay Therapeutics in a research report issued to clients and investors on Wednesday, May 7th. HC Wainwright analyst R. Burns now forecasts that the company will earn ($0.49) per share for the quarter, up from their prior estimate of ($0.53). HC Wainwright has a "Buy" rating and a $16.00 price objective on the stock. The consensus estimate for Relay Therapeutics' current full-year earnings is ($2.55) per share. HC Wainwright also issued estimates for Relay Therapeutics' Q3 2025 earnings at ($0.48) EPS, Q4 2025 earnings at ($0.49) EPS and FY2025 earnings at ($1.92) EPS.

Several other equities research analysts have also commented on RLAY. The Goldman Sachs Group cut their target price on Relay Therapeutics from $20.00 to $18.00 and set a "buy" rating on the stock in a research report on Thursday, February 27th. Stifel Nicolaus cut their price target on Relay Therapeutics from $27.00 to $23.00 and set a "buy" rating on the stock in a report on Thursday, February 27th. Wells Fargo & Company initiated coverage on shares of Relay Therapeutics in a research report on Thursday, April 17th. They set an "equal weight" rating and a $4.00 price objective for the company. Finally, Guggenheim dropped their target price on shares of Relay Therapeutics from $30.00 to $10.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Two analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $17.67.

Relay Therapeutics Stock Up 1.6%

Relay Therapeutics stock traded up $0.05 during trading hours on Monday, reaching $2.84. 121,677 shares of the company's stock were exchanged, compared to its average volume of 2,066,715. The firm's 50 day simple moving average is $2.88 and its 200 day simple moving average is $3.97. Relay Therapeutics has a twelve month low of $1.78 and a twelve month high of $10.72. The firm has a market capitalization of $486.05 million, a PE ratio of -1.08 and a beta of 1.65.

Relay Therapeutics (NASDAQ:RLAY - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported ($0.46) earnings per share for the quarter, topping analysts' consensus estimates of ($0.50) by $0.04. The firm had revenue of $7.68 million for the quarter, compared to the consensus estimate of $0.01 million. Relay Therapeutics's quarterly revenue was down 23.0% on a year-over-year basis. During the same period in the prior year, the business earned ($0.62) EPS.

Insider Buying and Selling at Relay Therapeutics

In related news, insider Peter Rahmer sold 10,739 shares of the firm's stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $3.00, for a total value of $32,217.00. Following the transaction, the insider now owns 390,081 shares of the company's stock, valued at approximately $1,170,243. This trade represents a 2.68% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Sanjiv Patel sold 61,422 shares of the stock in a transaction that occurred on Wednesday, April 23rd. The stock was sold at an average price of $2.97, for a total value of $182,423.34. Following the completion of the sale, the chief executive officer now directly owns 821,667 shares of the company's stock, valued at approximately $2,440,350.99. This trade represents a 6.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 94,320 shares of company stock valued at $280,981. Corporate insiders own 4.32% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Franklin Resources Inc. lifted its stake in Relay Therapeutics by 3,883.8% in the third quarter. Franklin Resources Inc. now owns 1,396,842 shares of the company's stock valued at $9,429,000 after purchasing an additional 1,361,779 shares during the last quarter. Barclays PLC raised its stake in shares of Relay Therapeutics by 118.4% in the third quarter. Barclays PLC now owns 251,819 shares of the company's stock valued at $1,783,000 after buying an additional 136,541 shares during the period. Raymond James Financial Inc. purchased a new position in shares of Relay Therapeutics during the 4th quarter valued at $779,000. Teacher Retirement System of Texas lifted its position in shares of Relay Therapeutics by 19.5% during the 4th quarter. Teacher Retirement System of Texas now owns 33,720 shares of the company's stock valued at $139,000 after buying an additional 5,492 shares during the last quarter. Finally, Norges Bank bought a new position in shares of Relay Therapeutics during the 4th quarter worth $23,821,000. 96.98% of the stock is owned by institutional investors.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.